In addition, approximately 30% of the patients in this trial had psoriatic arthritis ... the dosing regimen—is required. In summary, the ACCEPT trial demonstrated the superiority of ustekinumab ...

The product is indicated for the treatment of Crohn’s disease, paediatric plaque psoriasis, paediatric psoriatic arthritis ... dose vial for intravenous infusion at 130 mg/26 mL. Ustekinumab ...

Johnson & Johnson has filed its IL-23 inhibitor Tremfya for approval in psoriatic arthritis (PsA), its second ... blockbuster IL-12 and IL-23 inhibitor Stelara (ustekinumab) – has been approved ...

STEQEYMA®, one of the first-wave biosimilars to STELARA®, is now available in the U.S.Approved for the same indications as the reference product, STEQEYMA will be priced with a wholesale acquisition ...

Sotyktu significantly outperformed placebo for the treatment of psoriatic arthritis in a phase 3 trial ... Four biosimilars for Stelara have launched in the United States this year following ...

STEQEYMA® (ustekinumab-stba) is Celltrion's biosimilar to STELARA® (ustekinumab), which was launched on March 12, 2025Celltrion's adalimumab-aaty was previously added to the Costco Member ...

It encompasses all indications approved for the STELARA reference product, including psoriasis (PsO), psoriatic arthritis (PsA ... 1 mL solution in a single-dose, prefilled syringe.

It encompasses all indications approved for the STELARA ® reference product, including psoriasis (PsO), psoriatic arthritis (PsA ... 1 mL solution in a single-dose, prefilled syringe.